Cell by Cell Mapping of the Cancer Transcriptome
Capturing Tumor Heterogeneity for Better Therapeutics and Diagnostics
Scaledown Keeps Processes on the Up and Up
Minireactors, Sampling Techniques, and Statistical Analyses Can Keep Optimization Conversations Going
Streamlining Stem Cell Manufacturing
The Factory System Will Help the Stem Cell Industry Standardize, Integrate, and Automate Unit Operations
More Tooth, More Tail in CRISPR Operations
The Most Interesting Thing about CRISPR/Cas9 Is What It Can Accomplish in the Hands of Gifted Researchers
For full access to this article login to GEN Select now.
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
- With some medical interventions, immunogenicity is the whole point—hence the “good” immunogenicity provoked by vaccines. Immunogenicity is much to be avoided, however, when biotherapeutics are deployed. Biotherapeutics such as recombinant proteins or monoclonal antibodies (mAbs) may instigate “bad” immunogenicity, potentially nullifying any hoped-for benefits or even causing autoimmune reactions. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.